Edwards Lifesciences Corporation $EW Stake Reduced by Praxis Investment Management Inc.

Praxis Investment Management Inc. reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,960 shares of the medical research company’s stock after selling 1,960 shares during the quarter. Praxis Investment Management Inc.’s holdings in Edwards Lifesciences were worth $1,326,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Jennison Associates LLC grew its stake in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after buying an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after buying an additional 264,311 shares during the last quarter. Nuveen LLC bought a new position in Edwards Lifesciences during the 1st quarter worth $330,881,000. Invesco Ltd. grew its stake in Edwards Lifesciences by 2.6% during the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after buying an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Edwards Lifesciences by 5.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after buying an additional 198,882 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EW. Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Mizuho increased their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Wells Fargo & Company increased their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Trading Up 2.5%

Shares of EW stock opened at $74.50 on Friday. The stock has a 50-day simple moving average of $77.54 and a 200 day simple moving average of $76.16. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00. The stock has a market capitalization of $43.74 billion, a P/E ratio of 10.72, a P/E/G ratio of 3.49 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the business posted $0.70 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.